BioSpace News Archive

Group consolidated accounts have been prepared for the fourth quarter, and full year, which includes the consolidation of NeoDynamics AB, NeoDynamics GmbH and NeoDynamics Inc.

Dr Luca Cassetta and Professor Jeff Pollard have authored a major Perspectives review in Nature Reviews Cancer, detailing the seminal discoveries in macrophage biology over the past 50 years, revealing exciting future prospects for developing precision medicines to modulate macrophages for the treatment of cancer by targeting tumour associated macrophage in the tumour microenvironment.

FibroGen, Inc. will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close.

TransCode Therapeutics, Inc. announced the closing of its previously announced registered direct offering of 2,846,300 shares of common stock priced at-the-market under Nasdaq rules at $0.527 per share for gross proceeds of $1.5 million.

GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) (“GHG” or the “Company”) is pleased to announce the addition of Mathieu Couillard and the continuing engagement of Twilight Capital on its Advisory Board.

Covalon Technologies Ltd., an advanced medical technologies company, will release its Q1 Fiscal 2023 financial results on Thursday, February 23, 2023, before markets open.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the U.S. Food and Drug Administration has approved SYFOVRE™ for the treatment of geographic atrophy secondary to age-related macular degeneration.

LumiraDx Limited announced that it has received confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved AUSTEDO XR extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease.

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. has received accelerated approval from the U.S. Food and Drug Administration for FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.